The EV-302/KN-A39 trial demonstrated improved overall survival and PFS with Padcev and Keytruda compared to standard chemotherapy. Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in patients with locally advanced or metastatic ... peripheral sensory neuropathy (51.8%), ...